<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="9c983738-f481-4e39-b812-69b45c7e9401"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use MUPIROCIN CREAM safely and effectively. See full prescribing information for MUPIROCIN CREAM.<br/>
      <br/>MUPIROCIN cream, for topical use<br/>Initial U.S. Approval: 1987</title>
   <effectiveTime value="20250318"/>
   <setId root="0580458d-7178-4031-8ac7-0cda281ade8b"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="650574663" root="1.3.6.1.4.1.519.1"/>
            <name>Alembic Pharmaceuticals Limited</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="650574663" root="1.3.6.1.4.1.519.1"/>
                  <name>Alembic Pharmaceuticals Limited</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="871411532" root="1.3.6.1.4.1.519.1"/>
                        <name>Alembic Pharmaceuticals Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="46708-624" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="46708-624" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="af731590-a3c7-4e8c-aa93-a963e789a9c2"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250318"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="46708-624" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MUPIROCIN</name>
                        <formCode code="C28944" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CREAM"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>MUPIROCIN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="20" unit="mg"/>
                              <denominator value="1" unit="g"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="RG38I2P540" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MUPIROCIN CALCIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="D0GX863OA5" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MUPIROCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LKG8494WBH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="230OU9XXE4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL MONOSTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T5L8T28FGP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HIE492ZZ3T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENOXYETHANOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="YRC528SWUY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYOXYL 20 CETOSTEARYL ETHER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="TTV12P4NEE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>XANTHAN GUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="46708-624-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250318"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="46708-624-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250318"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA213053" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250318"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="36516fd5-d615-45b6-9df0-36651c718525"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID2">Mupirocin cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm<sup>2</sup>in area) due to susceptible isolates of <content styleCode="italics">Staphylococcus aureus (S. aureus)</content> and <content styleCode="italics">Streptococcus pyogenes (S. pyogenes)</content>.</paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID71">Mupirocin cream is an RNA synthetase inhibitor antibacterial indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm<sup>2</sup> in area) due to susceptible isolates of <content styleCode="italics">Staphylococcus aureus</content> and <content styleCode="italics">Streptococcus pyogenes</content>. (<linkHtml href="#ID1">1</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID3">
               <id root="2b5d7b85-8b21-4e1e-9fc6-dd8f0383db2e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <list listType="unordered" ID="ID73" styleCode="Disc">
                     <item>  For Topical Use Only.</item>
                     <item>  Apply a small amount of mupirocin cream, with a cotton swab or gauze pad, to the affected area 3 times daily for 10 days.</item>
                     <item>  Cover the treated area with gauze dressing if desired.</item>
                     <item>  Re-evaluate patients not showing a clinical response within 3 to 5 days.</item>
                     <item>  Mupirocin cream is not for intranasal, ophthalmic, or other mucosal use <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID15">5.2</linkHtml>, <linkHtml href="#ID23">5.6</linkHtml>)].</content>
                     </item>
                     <item>  Do not apply mupirocin cream concurrently with any other lotions, creams or ointments <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID48">12.3</linkHtml>)].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID5" styleCode="Disc">
                           <item>For Topical Use Only. (<linkHtml href="#ID3">2</linkHtml>)</item>
                           <item>Apply a small amount of mupirocin cream, with a cotton swab or gauze pad, to the affected area 3 times daily for 10 days. (<linkHtml href="#ID3">2</linkHtml>)</item>
                           <item>Re-evaluate patients not showing a clinical response within 3 to 5 days. (<linkHtml href="#ID3">2</linkHtml>)</item>
                           <item>Not for intranasal, ophthalmic, or other mucosal use. (<linkHtml href="#ID3">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID7">
               <id root="338cff82-af48-4a3a-bc47-413b2a19e0ee"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID8">Mupirocin cream USP, 2% is a white to off white cream that contains 20 mg (2% w/w) of mupirocin per gram in an oil-and water-based emulsion, supplied in 15-gram and 30-gram tubes.</paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID75">Cream: 20 mg (2% w/w) of mupirocin per gram in 15-gram and 30-gram tubes. (<linkHtml href="#ID7">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID9">
               <id root="7a974e57-0086-4ea4-ad87-31dbed234fa6"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID10">Mupirocin cream is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin cream.</paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID77">Known hypersensitivity to mupirocin or any of the excipients of mupirocin cream. (<linkHtml href="#ID9">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID11">
               <id root="6a91268a-56a3-4227-ba42-98bd151fe98a"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID12" styleCode="Disc">
                           <item>  Severe Allergic Reactions: Anaphylaxis, urticaria, angioedema, and generalized rash have been reported in patients treated with formulations of mupirocin, including mupirocin cream. (<linkHtml href="#ID13">5.1</linkHtml>)</item>
                           <item>  Eye Irritation: Avoid contact with eyes. (<linkHtml href="#ID15">5.2</linkHtml>)</item>
                           <item>  Local Irritation: Discontinue in the event of sensitization or severe local irritation. (<linkHtml href="#ID17">5.3</linkHtml>)</item>
                           <item>  <content styleCode="italics">Clostridium difficile</content> -Associated Diarrhea (CDAD): If diarrhea occurs, evaluate patients for CDAD. (<linkHtml href="#ID19">5.4</linkHtml>)</item>
                           <item>  Potential for Microbial Overgrowth: Prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (<linkHtml href="#ID21">5.5</linkHtml>)</item>
                           <item>  Risk Associated with Mucosal Use: Mupirocin cream is not formulated for use on mucosal surfaces. A separate formulation, BACTROBAN nasal ointment, is available for intranasal use. (<linkHtml href="#ID23">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID13">
                     <id root="1b4c4f2c-213c-426f-a20e-3f0a00fbcc5b"/>
                     <title>5.1 Severe Allergic Reactions</title>
                     <text>
                        <paragraph ID="ID14">Systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash, have been reported in patients treated with formulations of mupirocin, including mupirocin cream <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID30">6.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID15">
                     <id root="3483b878-9929-4a0c-895f-82589938f52f"/>
                     <title>5.2 Eye Irritation</title>
                     <text>
                        <paragraph ID="ID16">Avoid contact with the eyes. In case of accidental contact, rinse well with water. </paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID17">
                     <id root="480cb99e-62d1-4669-899d-8bf71970c425"/>
                     <title>5.3 Local Irritation</title>
                     <text>
                        <paragraph ID="ID18">In the event of a sensitization or severe local irritation from mupirocin cream, usage should be discontinued, and appropriate alternative therapy for the infection instituted.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID19">
                     <id root="7a4b35bc-4baf-4a96-9916-587b1b4ae789"/>
                     <title styleCode="italics">5.4 <content styleCode="italics">Clostridium difficile</content>-Associated Diarrhea</title>
                     <text>
                        <paragraph ID="ID20">
                           <content styleCode="italics">Clostridium difficile</content>-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID21">
                     <id root="149ec116-9a9f-40c0-99a6-2f864e988fd4"/>
                     <title>5.5 Potential for Microbial Overgrowth</title>
                     <text>
                        <paragraph ID="ID22">As with other antibacterial products, prolonged use of mupirocin cream may result in overgrowth of nonsusceptible microorganisms, including fungi <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID3">2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID23">
                     <id root="11f618df-b355-4c9f-9d29-f621a0a0fb31"/>
                     <title>5.6 Risk Associated with Mucosal Use</title>
                     <text>
                        <paragraph ID="ID24">Mupirocin cream is not formulated for use on mucosal surfaces. A separate formulation, BACTROBAN (mupirocin calcium) nasal ointment, is available for intranasal use. </paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID25">
               <id root="f83ea67c-1c5c-4d82-b614-670a94349e31"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID26">The following adverse reactions are discussed in more detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" ID="ID27" styleCode="Disc">
                     <item>Severe      Allergic Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID13">5.1</linkHtml>)]</content>
                     </item>
                     <item>Eye      Irritation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID15">5.2</linkHtml>)]</content>
                     </item>
                     <item>Local      Irritation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID17">5.3</linkHtml>)]</content>
                     </item>
                     <item>
                        <content styleCode="italics">Clostridium      difficile</content> -Associated Diarrhea <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID19">5.4</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250318"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID81">The most frequent adverse reactions (at least 1%) were headache, rash, and nausea. (<linkHtml href="#ID28">6.1</linkHtml>)</paragraph>
                        <paragraph ID="ID82">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID28">
                     <id root="35fa1e5f-28d5-4b25-9c9e-f0af63fa5d10"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID29">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In 2 randomized, double‑blind, double‑dummy trials, 339 subjects were treated with topical mupirocin cream plus oral placebo. Adverse reactions occurred in 28 (8.3%) subjects. The following adverse reactions were reported by at least 1% of subjects in connection with the use of mupirocin cream in clinical trials: headache (1.7%), rash (1.1%), and nausea (1.1%).</paragraph>
                        <paragraph>Other adverse reactions which occurred in less than 1% of subjects were: abdominal pain, burning at application site, cellulitis, dermatitis, dizziness, pruritus, secondary wound infection, and ulcerative stomatitis. </paragraph>
                        <paragraph>In a supportive trial in the treatment of secondarily infected eczema, 82 subjects were treated with mupirocin cream. The incidence of adverse reactions was as follows: nausea (4.9%), headache and burning at application site (3.6% each), pruritus (2.4%), and 1 report each of abdominal pain, bleeding secondary to eczema, pain secondary to eczema, hives, dry skin, and rash.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID30">
                     <id root="d832bc12-d380-4a7c-8d70-1f62118a6565"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID31">In addition to adverse reactions reported from clinical trials, the following reactions have been identified during postmarketing use of mupirocin cream. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal relationship to mupirocin cream.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune System Disorders</content>
                        </paragraph>
                        <paragraph>Systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID13">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID32">
               <id root="c6be8032-39ec-4055-b42d-9feea139f689"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250318"/>
               <component>
                  <section ID="ID33">
                     <id root="9e0ee7e6-71e5-4db1-b05f-2c5c2d106c78"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID34">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are insufficient human data to establish whether there is a drug-associated risk with mupirocin cream in pregnant women. Systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin cream<content styleCode="italics"> [see Clinical Pharmacology (<linkHtml href="#ID48">12.3</linkHtml>)]</content>. No developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area).</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data: </content>Developmental toxicity studies have been performed with mupirocin administered subcutaneously to rats and rabbits at doses up to 160 mg per kg per day during organogenesis. This dose is 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) based on calculations of dose divided by the entire body surface area. Maternal toxicity was observed (body weight loss/decreased body weight gain and reduced feeding) in both species with no evidence of developmental toxicity in rats. In rabbits, excessive maternal toxicity at the high dose precluded the evaluation of fetal outcomes. There was no developmental toxicity in rabbits at 40 mg per kg per day, 11 times the human topical dose based on calculations of dose divided by the entire body surface area.</paragraph>
                        <paragraph>Mupirocin administered subcutaneously to rats in a prenatal and postnatal development study (dosed during late gestation through lactation) was associated with reduced offspring viability in the early postnatal period at a dose of 106.7 mg per kg, in the presence of injection site irritation and/or subcutaneous hemorrhaging. This dose is 14 times the human topical dose based on calculations of dose divided by the entire body surface area. The no-observed adverse effect level in this study was 44.2 mg per kg per day, which is 6 times the human topical dose.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID35">
                     <id root="cfbb60ae-65a8-4f93-a6ae-0b6800dcb235"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID36">
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>It is not known whether mupirocin is present in human milk, has effects on the breastfed child, or has effects on milk production. However, breastfeeding is not expected to result in exposure of the child to the drug due to the minimal systemic absorption of mupirocin in humans following topical administration of mupirocin cream <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID48">12.3</linkHtml>)]</content>. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for mupirocin cream and any potential adverse effects on the breastfed child from mupirocin cream or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>To minimize oral exposure of the drug to children, a breast and/or nipple being treated with mupirocin cream should be thoroughly washed prior to breastfeeding.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID37">
                     <id root="d360b44c-e184-4d59-b1a5-08e341466479"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID38">The safety and effectiveness of mupirocin cream have been established in the age-groups 3 months to 16 years. Use of mupirocin cream in these age-groups is supported by evidence from adequate and well‑controlled trials of mupirocin cream in adults with additional data from 93 pediatric subjects studied as part of the pivotal trials in adults <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID55">14</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID39">
                     <id root="e31914ee-3e24-488a-a3f0-5a4cff92a394"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID40">In 2 adequate and well‑controlled trials, 30 subjects older than 65 years were treated with mupirocin cream. No overall difference in the efficacy or safety of mupirocin cream was observed in this patient population when compared with that observed in younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID41">
               <id root="6af733cf-b188-4813-981c-5d203dbf2cec"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID42">Mupirocin cream USP, 2% contains the dihydrate crystalline calcium hemi-salt of the RNA synthetase inhibitor antibacterial, mupirocin. Chemically, it is (α<content styleCode="italics">E</content>,2<content styleCode="italics">S</content>,3<content styleCode="italics">R</content>,4<content styleCode="italics">R</content>,5<content styleCode="italics">S</content>)-5-[(2<content styleCode="italics">S</content>,3<content styleCode="italics">S</content>,4<content styleCode="italics">S</content>,5<content styleCode="italics">S</content>)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-methyl-2<content styleCode="italics">H</content>-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dihydrate.</paragraph>
                  <paragraph>The molecular formula of mupirocin calcium is (C<sub>26</sub>H<sub>43</sub>O<sub>9</sub>)<sub>2</sub>Ca•2H<sub>2</sub>O, and the molecular weight is 1075.3. The molecular weight of mupirocin free acid is 500.6. The structural formula of mupirocin calcium is: </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID44">Each gram of mupirocin cream USP, 2% contains 20 mg (2% w/w) of mupirocin equivalent to 21.5 mg (2.15% w/w) of mupirocin calcium, USP. The inactive ingredients are benzyl alcohol, glycerol monostearate, mineral oil, phenoxyethanol, polyoxyl 20 cetostearyl ether, purified water, and xanthan gum.</paragraph>
               </text>
               <effectiveTime value="20250318"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9c983738-f481-4e39-b812-69b45c7e9401-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID45">
               <id root="de73a790-f346-408f-93ed-5dfe594f2706"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250318"/>
               <component>
                  <section ID="ID46">
                     <id root="6473e1c4-26af-40dd-9c47-7b835086dc64"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID47">Mupirocin is an RNA synthetase inhibitor antibacterial <content styleCode="italics">[see Microbiology (<linkHtml href="#ID50">12.4</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID48">
                     <id root="e233f9ae-f434-47c3-9404-cd27f271208e"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID49">
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Systemic absorption of mupirocin through intact human skin is minimal. The systemic absorption of mupirocin was studied following application of mupirocin cream 3 times daily for 5 days to various skin lesions greater than 10 cm in length or 100 cm<sup>2</sup> in area in 16 adults (aged 29 to 60 years) and 10 children (aged 3 to 12 years). Some systemic absorption was observed as evidenced by the detection of the metabolite, monic acid, in urine. Data from this trial indicated more frequent occurrence of percutaneous absorption in children (90% of subjects) compared with adults (44% of subjects); however, the observed urinary concentrations in children (0.07 to 1.3 mcg per mL [1 pediatric subject had no detectable level]) are within the observed range (0.08 to 10.03 mcg per mL [9 adults had no detectable level]) in the adult population. In general, the degree of percutaneous absorption following multiple dosing appears to be minimal in adults and children. </paragraph>
                        <paragraph>The effect of the concurrent application of mupirocin cream with other topical products has not been studied <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID3">2</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>In a trial conducted in 7 healthy adult male subjects, the elimination half-life after intravenous administration of mupirocin was 20 to 40 minutes for mupirocin and 30 to 80 minutes for monic acid.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>: Following intravenous or oral administration, mupirocin is rapidly metabolized. The principal metabolite, monic acid, demonstrates no antibacterial activity.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>: Monic acid is predominantly eliminated by renal excretion. </paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
               <component>
                  <section ID="ID50">
                     <id root="53b04bf5-b828-4c92-9c3f-aa86bf3b7dac"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph ID="ID51">Mupirocin is an RNA synthetase inhibitor antibacterial produced by fermentation using the organism <content styleCode="italics">Pseudomonas fluorescens</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <paragraph>Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl-transfer RNA (tRNA) synthetase.</paragraph>
                        <paragraph>Mupirocin is bactericidal at concentrations achieved by topical administration. Mupirocin is highly protein bound (greater than 97%) and the effect of wound secretions on the minimum inhibitory concentrations (MICs) of mupirocin has not been determined.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Resistance </content>
                        </paragraph>
                        <paragraph>When mupirocin resistance occurs, it results from the production of a modified isoleucyl-tRNA synthetase, or the acquisition of, by genetic transfer, a plasmid mediating a new isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance (MIC ≥512 mcg/mL) has been reported in increasing numbers of isolates of <content styleCode="italics">S. aureus</content> and with higher frequency in coagulase-negative staphylococci. Mupirocin resistance occurs with greater frequency in methicillin-resistant than methicillin-susceptible staphylococci.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cross Resistance </content>
                        </paragraph>
                        <paragraph>Due to its mode of action, mupirocin does not demonstrate cross resistance with other classes of antimicrobial agents.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity </content>
                        </paragraph>
                        <paragraph>Mupirocin has been shown to be active against susceptible isolates of <content styleCode="italics">S. aureus</content> and <content styleCode="italics">S. pyogenes</content>, both <content styleCode="italics">in vitro</content> and in clinical trials <content styleCode="italics">[see Indications and Usage (<linkHtml href="#ID1">1</linkHtml>)].</content> The following <content styleCode="italics">in vitro</content> data are available, but their clinical significance is unknown. Mupirocin is active against most isolates of <content styleCode="italics">Staphylococcus epidermidis</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Susceptibility Test Methods </content>
                        </paragraph>
                        <paragraph>High-level mupirocin resistance (≥512 mcg/mL) may be determined using standard disk diffusion or broth microdilution tests.<sup>1,2</sup> Because of the occurrence of mupirocin resistance in methicillin-resistant <content styleCode="italics">S. aureus</content> (MRSA), it is appropriate to test MRSA populations for mupirocin susceptibility prior to the use of mupirocin using a standardized method.<sup>3,4,5</sup>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID52">
               <id root="9709e3a0-a1a2-4e29-8c1b-a03f868354ad"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250318"/>
               <component>
                  <section ID="ID53">
                     <id root="47826e1a-a1f8-4671-a951-594eaeeba98e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID54">Long‑term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted.</paragraph>
                        <paragraph>Results of the following studies performed with mupirocin calcium or mupirocin sodium <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content> did not indicate a potential for genotoxicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, <content styleCode="italics">Salmonella</content> reversion test (Ames), <content styleCode="italics">Escherichia coli</content> mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice.</paragraph>
                        <paragraph>In a fertility/reproductive performance study (with dosing through lactation), mupirocin administered subcutaneously to male and female rats at doses up to 100 mg per kg per day which is 14 times the human topical dose (approximately 60 mg mupirocin per day) based on calculations of dose divided by the entire body surface area, did not result in impaired fertility or impaired reproductive performance attributable to mupirocin.</paragraph>
                     </text>
                     <effectiveTime value="20250318"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID55">
               <id root="dd517ae2-93ee-4f5d-b7f4-c8857329aa1d"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID56">The efficacy of topical mupirocin cream for the treatment of secondarily infected traumatic skin lesions (e.g., lacerations, sutured wounds, and abrasions not more than 10 cm in length or 100 cm<sup>2</sup> in total area) was compared with that of oral cephalexin in 2 randomized, double‑blind, double‑dummy clinical trials. Clinical efficacy rates at follow‑up in the per-protocol populations (adults and pediatric subjects included) were 96.1% for mupirocin cream (n = 231) and 93.1% for oral cephalexin (n = 219). Pathogen eradication rates at follow‑up in the per-protocol populations were 100% for both mupirocin cream and oral cephalexin.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pediatrics</content>
                  </paragraph>
                  <paragraph>There were 93 pediatric subjects aged 2 weeks to 16 years enrolled per protocol in the secondarily infected skin lesion trials, although only 3 were younger than 2 years of age in the population treated with mupirocin cream. Subjects were randomized to either 10 days of topical mupirocin cream 3 times daily or 10 days of oral cephalexin (250 mg 4 times daily for subjects greater than 40 kg or 25 mg per kg per day oral suspension in 4 divided doses for subjects less than or equal to 40 kg). Clinical efficacy at follow‑up (7 to 12 days post-therapy) in the per-protocol populations was 97.7% (43 of 44) for mupirocin cream and 93.9% (46 of 49) for cephalexin.</paragraph>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="ID57">
               <id root="0707ec95-3ffe-403d-9b59-40796b4b668b"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <list listType="ordered" ID="ID58">
                     <item>Clinical and Laboratory Standards Institute (CLSI). <content styleCode="italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-sixth Informational Supplement.</content> CLSI document M100-S26. Clinical and Laboratory Standards Institute, 950 West Valley Rd., Suite 2500, Wayne, PA 19087, USA, 2016.</item>
                     <item>Patel J, Gorwitz RJ, et al. Mupirocin Resistance. <content styleCode="italics">Clinical Infectious Diseases. </content>2009; 49(6): 935-41.</item>
                     <item>Clinical and Laboratory Standards Institute (CLSI). <content styleCode="italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard</content> – Tenth Edition. CLSI document M07-A10. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.</item>
                     <item>Clinical and Laboratory Standards Institute (CLSI). <content styleCode="italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Twelfth Edition.</content> CLSI document M02-A12. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.</item>
                     <item>Finlay JE, Miller LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. <content styleCode="italics">Antimicrob Agents Chemother. </content>1997; 41(5):1137-1139.</item>
                  </list>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="ID59">
               <id root="fcde3d0f-61e4-4d55-b268-0f0b5e183602"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID60">Mupirocin cream USP, 2% is a white to off white cream that contains 20 mg (2% w/w) of mupirocin per gram in an oil-and water-based emulsion.</paragraph>
                  <paragraph>Mupirocin cream USP, 2% is supplied in 15-gram and 30-gram tubes.</paragraph>
                  <paragraph>NDC 46708-624-15 (15-gram tube)</paragraph>
                  <paragraph>NDC 46708-624-30 (30-gram tube)</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze. </paragraph>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="ID61">
               <id root="3f024269-f9f6-4b5a-9c71-248b6960c7b9"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID62">
                     <content styleCode="italics">Advise the patient to read the FDA-approved patient labeling (Patient Information).</content>
                  </paragraph>
                  <paragraph>Advise the patient to administer mupirocin cream as follows:</paragraph>
                  <list listType="unordered" ID="ID84" styleCode="Disc">
                     <item>Use mupirocin cream      only as directed by the healthcare provider. It is for external use only.      Avoid contact of mupirocin cream      with the eyes. If mupirocin cream      gets in the eyes, rinse thoroughly with water.</item>
                     <item>Do not use mupirocin cream      in the nose.</item>
                     <item>Wash your hands before and after applying mupirocin cream.</item>
                     <item>Use a gauze pad or cotton swab to apply a small      amount of mupirocin cream to the      affected area. The treated area may be covered by gauze dressing if      desired.</item>
                     <item>Report to the healthcare provider any signs of local      adverse reactions. mupirocin cream      should be stopped and the healthcare provider contacted if irritation,      severe itching, or rash occurs.</item>
                     <item>Report to the healthcare provider or go to the      nearest emergency room if severe allergic reactions, such as swelling of      the lips, face, or tongue, or wheezing occur <content styleCode="italics">[see Warnings and      Precautions (<linkHtml href="#ID13">5.1</linkHtml>)]</content> .</item>
                     <item>If no improvement is seen in 3 to 5 days, contact      the healthcare provider.</item>
                  </list>
                  <paragraph ID="ID85">Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Alembic Pharmaceuticals Limited</content>
                  </paragraph>
                  <paragraph>(Derma Division),</paragraph>
                  <paragraph>Karakhadi, Vadodara 391450, India.</paragraph>
                  <paragraph>Mfg. License No.: G/25/2216</paragraph>
                  <paragraph>PHARMACIST-DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT</paragraph>
                  <paragraph>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</paragraph>
                  <table ID="ID79" width="794" styleCode="Noautorules">
                     <col width="369"/>
                     <col width="425"/>
                     <tbody>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> PATIENT INFORMATION</content>
                              <br/>
                              <content styleCode="bold"> Mupirocin (mue-PIR-oh-sin)</content>
                              <br/>
                              <content styleCode="bold"> cream, for topical use</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> What is mupirocin cream?</content>
                              <br/> Mupirocin cream is a prescription medicine used on the skin (topical use) to treat certain skin infections caused by bacteria called <content styleCode="italics">Staphylococcus aureus</content>  and <content styleCode="italics">Streptococcus pyogenes</content> .<br/> It is not known if mupirocin cream is safe and effective in children under 3 months of age.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> Who should not use mupirocin cream?</content>
                              <br/>
                              <content styleCode="bold"> Do not use mupirocin cream if:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>you are allergic to mupirocin or any of the ingredients in mupirocin cream. See the end of this Patient Information leaflet for a complete list of the ingredients in mupirocin cream</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> What should I tell my healthcare provider before using mupirocin cream?</content>
                              <br/>
                              <content styleCode="bold"> Before using mupirocin cream, tell your healthcare provider about all of your medical conditions including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>are pregnant or plan to become pregnant. It is not known if mupirocin cream will harm your unborn baby.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if mupirocin cream passes into your breast milk. You and your healthcare provider should decide if you can use mupirocin cream while breastfeeding.</item>
                              </list>
                              <content styleCode="bold"> Tell your healthcare provider about all of the medicines you take,</content>  including prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not mix mupirocin cream with other lotions, creams, or ointments.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> How should I use mupirocin cream?</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Mupirocin cream is for use on the skin (topical). Do not get mupirocin cream in your eyes, nose, mouth, or vagina (mucosal surfaces).</item>
                                 <item>Use mupirocin cream exactly as your healthcare provider tells you to use it. </item>
                                 <item>Apply a small amount of mupirocin cream, with a cotton swab or gauze pad, to the affected area 3 times each day. Apply mupirocin cream for 10 days.</item>
                                 <item>It is important that you take the full course of mupirocin cream not stop early because your symptoms may disappear before the infection is fully cleared.</item>
                                 <item>Wash your hands before and after applying mupirocin cream.</item>
                                 <item>After applying mupirocin cream, you may cover the treated area with a clean gauze pad, unless your healthcare provider has told you to leave it uncovered.</item>
                                 <item>Talk to your healthcare provider if your skin does not improve after 3 to 5 days of treatment with mupirocin cream.</item>
                                 <item>If you are breastfeeding and use mupirocin cream on your breast or nipple, wash the area well before breastfeeding your child.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode=" Lrule Rrule" align="left">
                              <content styleCode="bold"> What are the possible side effects of mupirocin cream?</content>
                              <br/>
                              <content styleCode="bold"> Mupirocin cream may cause serious side effects, including: </content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold"> severe allergic reactions</content> . Stop using mupirocin cream and call your healthcare provider or go to the nearest emergency room right away if you have any of the following signs or symptoms of a severe allergic reaction:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule" align="left">               ○  hives<br/>
                           </td>
                           <td valign="top" styleCode=" Rrule" align="left">    ○  trouble breathing or wheezing<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule" align="left">               ○  swelling of your face, lips, mouth, or tongue  <br/>
                           </td>
                           <td valign="top" styleCode=" Rrule" align="left">    ○  dizziness, fast heartbeat, or pounding in your chest<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule" align="left">               ○  a rash over your whole body   <br/>
                           </td>
                           <td valign="top" styleCode=" Rrule"/>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold"> eye irritation</content> . Do not get mupirocin cream in your eyes. If mupirocin cream gets in your eyes, rinse your eyes well with water.</item>
                                 <item>
                                    <content styleCode="bold"> irritation in the area mupirocin cream is used</content> . A rash may occur after using mupirocin cream and can be severe. Stop using mupirocin cream and call your healthcare provider if you develop an irritation, severe itching, or a rash while using mupirocin cream.</item>
                                 <item>
                                    <content styleCode="bold"> a type of diarrhea called <content styleCode="italics">clostridium difficile</content> -associated diarrhea (CDAD).</content>  CDAD may happen in people who use or have used medicine to treat bacterial infections. The severity of CDAD can range from mild diarrhea to severe diarrhea that may cause death (fatal colitis). Call your healthcare provider or go to the nearest emergency room right away if you have diarrhea while using or after you stop using mupirocin cream.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left"> The most common side effects of mupirocin cream include:<br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>headache</item>
                                 <item>rash</item>
                                 <item>nausea</item>
                              </list>
 These are not all the possible side effects of mupirocin cream. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> How should I store mupirocin cream?</content>
                              <br/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store mupirocin cream at room temperature between 68°F to 77°F (20°C to 25°C). </item>
                                 <item>Do not freeze mupirocin cream.</item>
                                 <item>
                                    <content styleCode="bold"> Keep mupirocin cream and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> General information about the safe and effective use of mupirocin cream.</content>
                              <br/> Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use mupirocin cream for a condition for which it was not prescribed. Do not give mupirocin cream to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about mupirocin cream that is written for health professionals.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> What are the ingredients in mupirocin cream?</content>
                              <br/>
                              <content styleCode="bold"> Active Ingredient:</content>  mupirocin calcium<br/>
                              <content styleCode="bold"> Inactive Ingredients:</content>  benzyl alcohol, glycerol monostearate, mineral oil, phenoxyethanol, polyoxyl 20 cetostearyl ether, purified water, and xanthan gum.<br/> Manufactured by:<br/>
                              <content styleCode="bold"> Alembic Pharmaceuticals Limited</content>
                              <br/> (Derma Division),<br/> Karakhadi, Vadodara 391450, India.<br/> Mfg. License No.: G/25/2216<br/> For more information, call 1-866-210-9797<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID64">This Patient Information has been approved by the U.S. Food and Drug Administration<content styleCode="bold">    </content>Revised: 03/2025</paragraph>
               </text>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="ID86">
               <id root="5b3c46c1-5d90-4cea-b0a6-d037bd5b2dcf"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <effectiveTime value="20250318"/>
            </section>
         </component>
         <component>
            <section ID="ID65">
               <id root="d9425907-d0d5-4c40-a43f-76de46a7da2e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID66">
                     <content styleCode="bold">15 gram Tube label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 46708-624-15 </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">15 grams</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Mupirocin C</content>
                     <content styleCode="bold">ream USP, 2%</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID68">
                     <content styleCode="bold">15 gram Carton label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 46708-624-15 </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">15 grams</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Mupirocin C</content>
                     <content styleCode="bold">ream USP, 2%</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250318"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>15 g tube</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9c983738-f481-4e39-b812-69b45c7e9401-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>15 g carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="9c983738-f481-4e39-b812-69b45c7e9401-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>